Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-1,41%
1 076,13
-15,38
-1,41%
—1 091,511 090,401 090,401 073,69——
SIXC
Communications
SIXC
Communications
SIXC
-0,55%
606,74
-3,37
-0,55%
—610,11610,11610,29606,17——
SIXE
Energy
SIXE
Energy
SIXE
+0,88%
1 248,82
+10,84
+0,88%
—1 237,981 237,831 252,411 225,03——
SIXI
Industrials
SIXI
Industrials
SIXI
-1,17%
1 724,36
-20,35
-1,17%
—1 744,711 740,951 747,291 721,57——
SIXM
Financials
SIXM
Financials
SIXM
-0,72%
635,59
-4,59
-0,72%
—640,18639,92643,19634,73——
SIXR
Staples
SIXR
Staples
SIXR
-0,76%
843,15
-6,43
-0,76%
—849,58845,27851,68839,47——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,55%
216,29
-1,19
-0,55%
—217,48217,48218,16215,51——
SIXT
Technology
SIXT
Technology
SIXT
+0,08%
3 263,41
+2,72
+0,08%
—3 260,693 273,363 287,813 240,78——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,34%
939,24
-3,21
-0,34%
—942,45939,39948,80933,98——
SIXV
Health care
SIXV
Health care
SIXV
-0,29%
1 462,56
-4,24
-0,29%
—1 466,801 464,701 467,191 458,36——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0,71%
2 380,40
-17,10
-0,71%
—2 397,502 395,032 412,012 370,64——
Q1 2026 earnings • in 1 day
See details
ONC:NASDAQ
BeOne Medicines AG
297,14 $
+1,12%
(+3,28) 1D
297,14 $
0,00% (0,00)
After hours
Closed: 4 մյս, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ONC...
Open
293,88 $
High
300,76 $
Low
293,50 $
Mkt. cap
35,55 մլրդ
Avg. vol.
203,86 հզր
Volume
135,82 հզր
52-wk high
385,22 $
52-wk low
218,31 $
Beta
0,50
Shares outstanding
118,57 մլն
No. of employees
12 հզր
News stories
From sources across the web
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market. BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12 հզր
Founded28 հոկ, 2010 թ.
Headquarters-
Sector-
Websitebeonemedicines.com
Next call in 32:47:26
մյս 6, չրք, 08:00
Fiscal Period
Q1 2026
Normalized EPS / Estimate
-/ (0,81 est.)USD
Revenue / Estimate
-/ (1,44 մլրդ est.)USD
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025 թ. մրտ
2025 թ. հնս
2025 թ. սեպ
2025 թ. դեկ
Revenue
1,12 մլրդ
1,32 մլրդ
1,41 մլրդ
1,50 մլրդ
Cost of goods sold
165,00 մլն
164,61 մլն
196,51 մլն
142,42 մլն
Cost of revenue
165,00 մլն
164,61 մլն
196,51 մլն
142,42 մլն
Research and development expenses
481,89 մլն
524,90 մլն
523,66 մլն
615,42 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
459,29 մլն
537,91 մլն
529,00 մլն
555,29 մլն
Operating expense
941,18 մլն
1,06 մլրդ
1,05 մլրդ
1,17 մլրդ
Total operating expenses
1,11 մլրդ
1,23 մլրդ
1,25 մլրդ
1,31 մլրդ
Operating income
11,10 մլն
87,88 մլն
163,11 մլն
185,04 մլն
Other non operating income
19,38 մլն
13,19 մլն
-4,76 մլն
4,16 մլն
EBT including unusual items
20,90 մլն
99,55 մլն
147,16 մլն
149,24 մլն
EBT excluding unusual items
22,96 մլն
102,67 մլն
160,80 մլն
189,96 մլն
Income tax expense
19,63 մլն
5,23 մլն
22,32 մլն
82,74 մլն
Effective tax rate
93,92%
5,25%
15,17%
55,44%
Other operating expenses
-
-
-
-
Net income
1,27 մլն
94,32 մլն
124,84 մլն
66,50 մլն
Net profit margin
0,11%
7,17%
8,84%
4,44%
Earnings per share
-
0,84
1,09
0,58
Interest and investment income
12,85 մլն
11,49 մլն
13,79 մլն
32,37 մլն
Interest expense
-7,00 մլն
-7,99 մլն
-10,76 մլն
-32,47 մլն
Net interest expenses
5,85 մլն
3,50 մլն
3,03 մլն
-103,00 հզր
Depreciation and amortization charges
-
-
-
-
EBITDA
42,73 մլն
117,75 մլն
198,86 մլն
219,47 մլն
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer